New digital PET/CT could spot hidden artery inflammation and prevent blindness

NCT ID NCT05000138

Completed Diagnosis Sponsor: Jewish General Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

Giant cell arteritis (GCA) causes inflamed arteries and can lead to blindness if not treated quickly. This study tested a new digital PET/CT scan that can see tiny arteries in the head, which older scans missed. 92 patients with suspected GCA got both a PET/CT and an ultrasound. Researchers compared the scans to see if the new PET/CT could be a one-stop test for faster, more accurate diagnosis.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: FDG (radioactive glucose) injected for PET/CT scan
What this could lead to: If successful, digital PET/CT could become a single, reliable test to quickly diagnose giant cell arteritis, reducing the risk of blindness.
What could go wrong: This is a small, completed study (92 participants) comparing PET/CT to ultrasound. The new scan may not be accurate enough to replace current methods, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GIANT CELL ARTERITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Giant Cell Arteritis temporal arteritis vasculitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GIANT CELL ARTERITIS VASCULITIS

Contacts and locations

Locations

CHUS

Sherbrooke, Quebec, H3T1C5, Canada
Hôpital du Sacré-Cœur de Montréal

Montreal, Quebec, H4J 1C5, Canada
Jewish General Hospital

Montreal, Quebec, H4R3E8, Canada
University Medical Center Groningen

Groningen, Netherlands
Université Bourgogne Europe, Centre Georges-François Leclerc

Dijon, 21000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.